50 Science Park Road, Level 2, The Kendall
Science Park II
17 articles with Vela Diagnostics
FDA Grants De Novo Designation for Vela Diagnostics’ Next Generation Sequencing HIV-1 Genotyping Assay
Vela Diagnostics’ Sentosa® SQ HIV-1 Genotyping Assay is the first FDA De Novo designated Next Generation Sequencing (NGS) assay for detecting HIV-1 drug resistance mutations (DRMs).
The Eastern Pathology Alliance to offer Hepatitis C testing services to the wider NHS capitalising on next generation sequencing technology
The Eastern Pathology Alliance (EPA) announces today that it is to offer Hepatitis C genotyping testing to the wider NHS nationally leveraging its investment in next generation sequencing assays.
Vela Diagnostics Announces FDA Submission of its Next Generation Sequencing (NGS) HIV Genotyping and Drug Resistance Mutation (DRM) Assay
Vela announces FDA submission for the Sentosa® SQ HIV Genotyping Assay, a Next Generation Sequencing (NGS) genotyping and drug resistance mutation (DRM) detection in vitro diagnostic test intended for use as an aid in monitoring and treating HIV-1 infection
First Next-Generation Sequencing Test For HIV Drug Resistance Could Help Combat AIDS Worldwide, Vela Diagnostics Reveals
Vela Diagnostics Announces Launch Of CE-IVD Non-Small Cell Lung Cancer Next-Generation Sequencing Panel
Vela Diagnostics Announces The Listing Of Their Next-Generation Sequencing System With The U.S. FDA As A Class II Medical Device
Vela Diagnostics Announces The Listing Of their Next-Generation Sequencing System With The U.S. FDA As A Class II Medical Device
Vela Diagnostics Announces Availability Of Non-Small Cell Lung Cancer (NSCLC) And Colorectal Cancer (CRC) Next-Generation Sequencing Panels For Early Access Customers
Vela Diagnostics Launches First CE-IVD Next-Generation Sequencing Oncology Panel For Melanoma Testing On The Automated Sentosa® NGS Workflow